Core Points - The internal audit system of Beijing Baijun Medical Technology Co., Ltd. aims to standardize internal audit work, clarify responsibilities, ensure audit quality, and enhance economic efficiency [1][2] - The internal audit is defined as an independent and objective evaluation of financial activities, internal controls, and risk management to promote governance and achieve organizational goals [1][2] - The internal audit's objectives include improving internal controls, managing costs effectively, enhancing operational management, mitigating operational risks, and increasing company value [1][2] Chapter Summaries Chapter 1: General Principles - The internal audit system is established to comply with relevant laws and regulations, ensuring the integrity of financial reporting and internal controls [1][2] - Internal controls are defined as processes that provide reasonable assurance regarding the achievement of objectives related to operational efficiency, compliance, and asset security [1] Chapter 2: Audit Institutions and Personnel - The board of directors is responsible for establishing and implementing internal control systems, with significant internal control systems requiring board approval [2] - An audit committee is established by the board, consisting of directors, with independent directors making up more than half and at least one being a professional accountant [2][3] - The internal audit department is responsible for supervising the authenticity and completeness of financial information and internal control systems [2][3] Chapter 3: Responsibilities and General Requirements - The audit committee guides and supervises the internal audit department, reviews annual audit plans, and reports on audit progress and significant issues to the board [2][3] - The internal audit department evaluates the completeness and effectiveness of internal control systems across the company and its subsidiaries [3][4] Chapter 4: Specific Implementation - The internal audit department must conduct evaluations of internal controls at least annually and report findings to the audit committee [6][7] - Audits of significant external investments, asset purchases, guarantees, and related transactions must be conducted promptly, focusing on compliance with approval procedures and contract execution [8][9][10] Chapter 5: Violations and Responsibilities - Violations of laws, regulations, or internal policies may result in penalties, including administrative or economic sanctions for individuals involved in misconduct [10][12] Chapter 6: Supplementary Provisions - The internal audit system will be interpreted and revised by the board of directors and will take effect upon board approval [11]

北京佰仁医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第三届董事会第十一次会议，审议通过了《关于取消公司监事会的议案》 《关于变更公司注册资本、修订 <公司章程> 并办理工商变更登记的议案》，同 日召开第三届监事会第八次会议，审议通过了《关于取消公司监事会的议案》。 现将有关情况说明如下： 证券代码：688198 证券简称：佰仁医疗 公告编号：2025-028 北京佰仁医疗科技股份有限公司 关于变更公司注册资本、取消监事会、修订《公司 章程》并办理工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、变更公司注册资本的情况 公司于 2025 年 6 月 13 日召开第三届董事会第十次会议、第三届监事会第 七次会议，审议通过了《关于公司 2020 年限制性股票激励计划首次授予部分第 五个归属期符合归属条件的议案》《关于公司 2020 年限制性股票激励计划预留 授予部分第三个归属期符合归属条件的议案》。2025 年 7 月 23 日，公司 2020 年 限制性股票激励计划首次授 ...

Core Points - The article outlines the information disclosure management system of Beijing Bairen Medical Technology Co., Ltd, aiming to enhance the quality of information disclosure and protect investors' rights [1][2][3] Group 1: General Principles - The company must disclose information truthfully, accurately, completely, and timely, avoiding any false records or misleading statements [2][3] - All investors should have equal access to significant information, and the company must not disclose information to select individuals or groups [2][3] - The company is required to establish an insider information management system to minimize the number of individuals privy to insider information before its public disclosure [2][3] Group 2: Disclosure Requirements - The company must disclose information that could significantly impact shareholders and stakeholders' decisions, ensuring that all shareholders have equal opportunities to access this information [2][3] - The content of announcements should be clear, concise, and free from excessive jargon or complex expressions [3][4] - The company must submit disclosure documents to the Shanghai Stock Exchange and publish them on designated media and websites [3][4] Group 3: Reporting Standards - The company is required to disclose significant information reflecting its business, technology, finance, governance, competitive advantages, industry trends, and risk factors [5][6] - Regular reports, including annual, semi-annual, and quarterly reports, must be disclosed within specified timeframes, ensuring that they contain all material information [9][10] - The company must disclose any major events that could affect its stock price or trading activities promptly [15][16] Group 4: Internal Management of Disclosure - The board of directors is responsible for overseeing the company's information disclosure, with the chairman being the final authority [27][28] - The board secretary is tasked with organizing and coordinating disclosure activities, ensuring compliance with regulations [27][28] - Senior management must ensure timely preparation and submission of reports for board review [28][29]

Core Points - The company, Beijing Bairen Medical Technology Co., Ltd., held its 11th meeting of the 3rd Board of Directors on August 27, 2025, where it approved the proposal to formulate and revise certain governance systems [1][2] - The revisions are in accordance with the current laws and regulations of the People's Republic of China, including the Company Law and Securities Law, aimed at promoting standardized operations within the company [1] - The specific governance systems being revised include the "Management System for Shares Held by Directors and Senior Management" and the "Rules for Shareholders' Meetings," with the latter being renamed [1] Governance System Changes - The company plans to revise several governance systems, specifically items 3 to 16 and item 25, which will be disclosed on the Shanghai Stock Exchange website simultaneously with this announcement [1]

Core Points - The document outlines the rules governing the behavior of the controlling shareholders and actual controllers of Beijing Bairen Medical Technology Co., Ltd, aiming to enhance corporate governance and ensure the company's healthy development [1][2][3] Group 1: General Principles - The rules are established to improve the corporate governance structure of the company and ensure its normal operation [1] - Controlling shareholders and actual controllers must comply with laws and regulations, exercising their rights without harming the interests of the company and other shareholders [2] - They are required to act in good faith, maintain the company's quality, and uphold the common interests of all shareholders [3] Group 2: Corporate Governance - Controlling shareholders and actual controllers must establish systems to clarify decision-making processes for significant matters and ensure the company's independence [5] - They should protect the integrity of the company's assets and not infringe upon the company's rights to its property [6] - They are prohibited from influencing the company's personnel independence and financial independence through improper means [9][10] Group 3: Information Disclosure - Controlling shareholders and actual controllers must fulfill their information disclosure obligations, ensuring that disclosed information is truthful, accurate, complete, and timely [6][7] - They must notify the company of significant events that could impact the company's securities trading prices [7][8] - They are required to maintain confidentiality regarding undisclosed significant information and not use it for personal gain [11][12] Group 4: Share Trading and Control Transfer - Controlling shareholders and actual controllers must adhere to legal regulations when trading company shares and must report any changes in shareholding that exceed specified thresholds [38][39] - They are prohibited from increasing their shareholding under certain conditions, such as during specific reporting periods [41] - Any transfer of control must be conducted fairly and without harming the interests of the company and other shareholders [42][43]

Core Viewpoint - The company is committed to enhancing operational quality, governance, and shareholder returns, aligning with national economic and financial directives to boost market confidence and support high-quality economic development [1]. Group 1: Business Focus and Product Development - The company is focusing on its core business by converting original research results into marketable products, thereby enhancing its core competitiveness [1]. - The company has received approval for its innovative transcatheter valve-in-valve product, which addresses the needs of patients with existing bioprosthetic valves, extending their durability [2]. - Multiple products, including eye biological patches and ePTFE materials, are progressing through the registration and clinical trial phases, ensuring a robust product pipeline for future growth [3]. Group 2: Shareholder Returns - The company has established a profit distribution plan for 2024, distributing a cash dividend of 0.80 yuan per share, totaling approximately 109.92 million yuan, which represents 75.12% of the net profit attributable to shareholders [4]. - The company has actively engaged in share buybacks, with the controlling shareholder increasing their stake by 124,759 shares, amounting to approximately 13.77 million yuan [5]. Group 3: Governance and Compliance - The company is enhancing its governance structure by revising internal policies and establishing new systems to ensure compliance and protect shareholder rights [6]. - The company has implemented a multi-level supervision mechanism for key personnel to ensure accountability and compliance with regulations [7]. Group 4: Investor Communication - The company has committed to transparent communication with investors, fulfilling its information disclosure obligations and ensuring the accuracy and timeliness of its reports [8]. - In the first half of 2025, the company released 27 reports and held performance briefings to engage with investors and convey its value proposition [8].

北京佰仁医疗科技股份有限公司 章 程 北京佰仁医疗科技股份有限公司章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织 和行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）和其他有关规定，制订本 章程。 第二条 北京佰仁医疗科技股份有限公司（以下简称"公司"）系依照《公 司法》和其他有关规定成立的股份有限公司。 公司由北京佰仁医疗科技有限公司整体变更方式设立，在北京市工商行政管 理局昌平分局登记注册，取得统一社会信用代码为 911101147770556682 的《营 业执照》。 第三条 公司于 2019 年 11 月 7 日经中国证券监督管理委员会（以下简称 "中国证监会"）证监许可〔2019〕2225 号文注册同意，首次向社会公众发行人 民币普通股 2,400 万股，于 2019 年 12 月 9 日在上海证券交易所科创板上市。 第四条 公司注册名称：北京佰仁医疗科技股份有限公司 公司英文名称：Beijing Balance Medical Technology Co.,Ltd. 第五条 公司住所：北京市昌平区 ...

Core Viewpoint - The document outlines the management system for the shares held by the directors and senior management of Beijing Bairen Medical Technology Co., Ltd, detailing the procedures and regulations governing shareholding and trading activities [1][2]. Summary by Sections General Provisions - The system is established to clarify the procedures for managing shares held by directors and senior management, in accordance with relevant laws and regulations [1]. - It applies to all shares registered under the names of directors and senior management [1]. Shareholding and Trading Rules - Directors and senior management can sell shares through the Shanghai Stock Exchange or other legally permitted methods, adhering to commitments regarding holding periods and trading methods [2]. - Specific conditions under which share reduction is prohibited include resignation within six months, ongoing investigations, and other legal restrictions [4][5]. Reporting and Disclosure - Directors and senior management must report personal information to the Shanghai Stock Exchange within two trading days of changes, including new appointments or resignations [2][3]. - A written notice of trading plans must be submitted to the board secretary before any share transactions, and trading cannot occur without the secretary's feedback [8][9]. Responsibilities and Penalties - Directors and senior management must ensure that their relatives and associated entities do not engage in insider trading [10]. - Violations of trading regulations may result in disciplinary actions from the company and regulatory authorities, including the recovery of profits from illegal trades [11][12]. Appendices - An attachment outlines the notification format for share trading plans, including details on the number of shares, trading period, and price range [12].

Core Points - The article outlines the profit distribution management system of Beijing Bairen Medical Technology Co., Ltd, aiming to establish a scientific, sustainable, and stable distribution mechanism to enhance transparency and protect investors' rights [1][2]. Chapter Summaries Chapter 1: General Principles - The company aims to regulate profit distribution behavior and enhance transparency in accordance with relevant laws and its articles of association [1]. Chapter 2: Profit Distribution Order - The company prioritizes reasonable returns for investors, especially minority shareholders, and outlines the order of profit distribution, including mandatory allocations to statutory reserves and provisions for loss compensation [2]. Chapter 3: Profit Distribution Policy - The company adopts a continuous and stable profit distribution policy, considering various factors such as investor returns, actual conditions, and future development goals [3][4]. Chapter 4: Supervision and Constraints - The audit committee is responsible for supervising the execution of profit distribution policies and decision-making processes [5]. Chapter 5: Execution and Information Disclosure - The company must strictly adhere to its cash dividend policy and disclose profit distribution plans in annual and semi-annual reports, ensuring compliance with its articles of association [6]. Chapter 6: Supplementary Provisions - The company reserves the right to modify the profit distribution system as per legal requirements and must seek shareholder approval for any changes [6].

华人民共和国证券法》、《上市公司监管指引第 8 号——上市公司资金往来、对 外担保的监管要求》、《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）等有关法律、行政法规、部门规章和规范性文件以及《北京佰仁医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际 情况，制定本制度。 北京佰仁医疗科技股份有限公司 规范与关联方资金往来管理制度 北京佰仁医疗科技股份有限公司 规范与关联方资金往来管理制度 第一章 总则 第一条 为了规范北京佰仁医疗科技股份有限公司（以下简称"公司"）与控 股股东、实际控制人及其他关联方（以下简称"公司关联方"）的资金往来，避免 公司关联方占用公司资金，保护公司、股东和其他利益相关人的合法权益，建立 防范公司关联方占用公司资金的长效机制，根据《中华人民共和国公司法》、 《中 第二条 公司及纳入公司合并会计报表范围的子公司与公司关联方之间进 行的资金往来适用本制度。 第三条 本制度所称公司关联方和关联交易的界定，遵从《上市规则》的规 定。 第四条 本制度所称资金占用，包括但不限于以下方式： （一） 经营性资金占用：是指公司关联方通过采购、销售等生产经营环 ...